Please login to the form below
Santarus begins Zegerid litigation against Par
US-based Santarus, is suing Par Pharmaceutical in the United States District Court for the District of Delaware for an alleged infringement of the patents listed in the FDA's Orange Book for Zegerid (omeprazole/sodium bicarbonate) capsules.
US-based Santarus, is suing Par Pharmaceutical in the United States District Court for the District of Delaware for an alleged infringement of the patents listed in the FDA's Orange Book for Zegerid (omeprazole/sodium bicarbonate) capsules.
The University of Missouri, which is licensor of the patents, has joined Santarus in the litigation as a co-plaintiff.
The lawsuit refers to an Abbreviated New Drug Application (ANDA) filed by Par with the FDA to market a generic version of Zegerid Capsules before the 2016 expiration of three listed US patents (6,645,988, 6,489,346 and 6,699,885).
Santarus filed the lawsuit within the 45 days limit required to prevent the FDA from approving París ANDA for 30 months, or until a district court decision ruling against Santarus.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
Senior External Communications Lead
-
£Competitive Salary
-
Account Director
-
£Competitive Salary
-
Account Manager (PR)
-
Great Benefits
-
Senior Account Manager
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Account Director – UK Office
-
Excellent salary and benefits
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
-
Account Manager
-
£Competitive Salary
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
- FDA grants emergency authorisation to chloroquine for COVID-19
- AbbVie suspends Kaletra patent rights as COVID-19 drug trials advance
- Novartis donates malaria drug for COVID-19 clinical trials
- Moderna and GSK advance coronavirus vaccine candidates
- Sanofi, Regeneron launch trials of arthritis drug Kevzara for COVID-19
- Germany's coronavirus infections climb but deaths remain low
- OSE lung cancer vaccine clears phase 3 hurdle, but COVID-19 stalls programme
- Clinical trial of Gilead’s coronavirus hopeful remdesivir begins in UK
- UK government reveals only 2,000 key NHS staff have been tested for coronavirus
- Today’s reality: how to make social distancing work in medcomms
- Q&A: Kate Paxton
- Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
PMHub
AMICULUM Limited
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...
Latest intelligence
- Delivering true value: what does it mean for KAM in cancer care?
- Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
- Pharma funding and M&A in 2020
- Why pharma M&A has continually bucked the trend...
- Behaviour change through medical education: How can we turn aspiration into reality?
- Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...
Quick links
Infographics
